# Krystexxa

NDC: 75987-080
Generic name: pegloticase
Labeler / Manufacturer: Horizon Therapeutics USA, Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, SOLUTION
Routes: INTRAVENOUS
Marketing started: 20100914

FDA application: BLA125293

## Active ingredients

- PEGLOTICASE: 8 mg/mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"75987-080"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=75987-080
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6e566303-d93a-4130-b764-25749829aa95